ேசை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ேசை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ேசை Today - Breaking & Trending Today

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant ....

Eisai Co Ltd , Associated Professional Sleep Societies , Poster Numbers , ேசை இணை லிமிடெட் , தொடர்புடையது ப்ரொஃபெஶநல் தூங்கு சமூகங்கள் ,

Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia


(0)
TOKYO, May 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society.
Through this alliance, Eisai and ITO EN aim to contribute to the solution of dementia, which is one of the important social issues, with integrating Eisai s wealth of experience and knowledge in drug creation and disease awareness activities in the area of dementia, as well as Eisai s solution measures such as digital technology, and ITO EN s customer network through its community-based sales activities, as well as ITO EN s problem-solving project related to cognitive function based on abundant research on Matcha (powdered green tea). The specific initiatives planned are as follows. ....

Eisai Co Ltd , Function Claims , ேசை இணை லிமிடெட் , செயல்பாடு கூற்றுக்கள் ,

Eisai and National Cancer Center Commence Joint Research and Development Project


Eisai and National Cancer Center Commence Joint Research and Development Project
Using PDX With High Predictability of Clinical Outcomes, and Cancer Genome Data
TOKYO, May 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers , and that research activities have commenced. This R&D project is to be carried out with funding under the program Cyclic Innovation for Clinical Empowerment (CiCLE) established by the Japan Agency for Medical Research and Development (AMED). ....

Eisai Co Ltd , National Cancer Center Japan , National Cancer Center , Japan Agency For Medical Research , Drug Discovery , Accelerate Development , Anti Cancer Drugs , Rare Cancers , High Predictability , Clinical Outcomes , Cancer Genome , Clinical Empowerment , Japan Agency , Medical Research , Patient Derived Xenografts , ேசை இணை லிமிடெட் , தேசிய புற்றுநோய் மையம் ஜப்பான் , தேசிய புற்றுநோய் மையம் , மருந்து கண்டுபிடிப்பு , விரைவுபடுத்து வளர்ச்சி , எதிர்ப்பு புற்றுநோய் மருந்துகள் , ரேர் புற்றுநோய்கள் , மருத்துவ ஔட்கம்ஸ் , புற்றுநோய் மரபணு , மருத்துவ அதிகாரம் , மருத்துவ ஆராய்ச்சி ,

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease


(1)
TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer s disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer s and Parkinson s Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab ....

John Hardy , Jeffrey Cummings , Philip Schelten , Development Code , Eisai Co Ltd , Sysmex Corporation , Biogen Inc , International Conference On Alzheimer , International Conference , Science Behind , Colin Masters , ஜான் ஹார்டி , ஜெஃப்ரி கம்மிங்ஸ் , வளர்ச்சி குறியீடு , ேசை இணை லிமிடெட் , பயோஜென் இன்க் , சர்வதேச மாநாடு ஆன் முதுமறதி , சர்வதேச மாநாடு , அறிவியல் பின்னால் , கொலின் முதுநிலை ,

Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya


Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya
TOKYO, Mar 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians. ....

Nairobi Area , Yoichi Shimada , Eisai Co Ltd , Amref Health Africa , Medlynks Kenya Ltd , Public Relations Department , Afya Co Ltd , Meru County , Eastern Province , Personal Protection Equipment , Connect Afya , Relations Department , Corona Virus , நைரோபி பரப்பளவு , யோச்சி ஶிமாட , ேசை இணை லிமிடெட் , பொது உறவுகள் துறை , மேரு கவுண்டி , கிழக்கு மாகாணம் , தனிப்பட்ட ப்ரொடெக்ஶந் உபகரணங்கள் , உறவுகள் துறை , கொரோனா வைரஸ் ,